Reducing drug costs requires more than just reducing a drug’s list price, Avalere Health Founder Dan Mendelson writes in a recent article published on Forbes.
Mendelson points to PCSK9 inhibitors as an example. While the PCSK9 manufacturers slashed the list price in a bid to improve patient access, the complex nature of prescription drug benefit programs can create unforeseen consequences.
The drugs were ranked into a “non-preferred” tier of drugs, which meant patients had to shoulder a significant portion of the costs.
“This is a serious systemic failure,” he writes.
To read the full article on Forbes, click here.